GlassScriptPhysician profile
John Laval Pare
NPI 1952395451
$4,770.66
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $380 · 2020: $684 · 2021: $1,499 · 2022: $834 · 2023: $993 · 2024: $381.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,374.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,373.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $676.54 | 2019-2024 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $642.64 | 2020-2023 | Breztri, Farxiga |
| Lilly USA, LLC | $529.53 | 2019-2024 | Mounjaro, Zepbound, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $404.64 | 2019-2024 | Jardiance |
| Abbvie INC. | $398.74 | 2021-2023 | |
| Glaxosmithkline, LLC. | $310.26 | 2021-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Amgen INC. | $277.04 | 2019-2024 | Repatha, Otezla |
| E.R. Squibb & Sons, L.L.C. | $265.34 | 2019-2023 | Camzyos |
| Cardiovascular Systems INC. | $194.53 | 2021 | |
| Amarin Pharma, INC. | $163.71 | 2020-2021 | |
| Pfizer INC. | $125.02 | 2019-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $125.00 | 2022 | |
| Exact Sciences Corporation | $92.23 | 2023-2024 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $66.66 | 2022-2023 | Quviviq |
| Astellas Pharma US INC | $65.41 | 2020-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $59.01 | 2022 | |
| Eisai INC. | $56.00 | 2020-2022 | |
| Otsuka America Pharmaceutical, INC. | $52.96 | 2023 | Rexulti |
| Vanda Pharmaceuticals INC. | $50.56 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $46.21 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $27.22 | 2019-2020 | |
| Allergan, INC. | $23.68 | 2020 | |
| Ironshore Pharmaceuticals INC. | $22.92 | 2019 | |
| Vertos Medical, INC. | $17.24 | 2024 | Mild Device Kit |
| Dexcom, INC. | $16.29 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.23 | 2020 | |
| Phathom Pharmaceuticals, INC. | $15.76 | 2024 | Voquezna |
| Biohaven Pharmaceuticals, INC. | $14.79 | 2021 | |
| Dermira, INC. | $14.50 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Pare listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.